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Summary: In many human tissues, fuel is stored for immediate use, as well as for energy exchange between
different parts of the body. Fat and glycogen represent, together with proteins, the principal energy storage
materials. During energy requirement, e.g. muscular exercise, glycogen as a local reserve, is used first to
supply energy needs. Acetyl-carnitine, as an active molecular group, represents an intermediate substrate,
usable directly in the working tissue. The present study investigates whether plasma acetyl-carnitine could be
a useful biochemical measure for information on fuel exchange in the body, and whether it is a rapidly
available energy source exchangeable among tissues with different metabolic functions, such as muscle and
liver. The present study investigated control and hepatopathic subjects after maximal and submaximal muscular
exercise. Hepatopathic patients may be a useful model, as liver carnitine metabolism is likely to be impaired.
Plasma acetyl-carnitine before, during and after maximal exercise in hepatopathic subjects did not differ,
while in normal subjects it increased. After submaximal exercise, acetyl-carnitine increased in patients, as well
in controls. In the patients (n = 9) with liver metabolism disorders we observed that during maximal exercise
plasma acetyl-carnitine varied from 3.26 + 2.18 μηιοΙ/1 (time 0 min) to 4.30 ± 2.02 μιηοΐ/ΐ (time 20 min) and
from 1.99 ± 1.36 μηιοΐ/ΐ to 4.83 ± 2.60 μηιοΐ/ΐ (ρ < 0.05) in the controls (n = 7). During submaximal
exercise, plasma acetyl-carnitine varied from 1.89 ±1.7 μηιοΙ/1 (time Omin) to 2.92 ± 2.22 μιηοΐ/ΐ (time
30 min) (p < 0.05) and to 4.32 ± 2.22 μηιοΙ/1 (recovery, time 90 min) in controls, while in patients there was
a significant variation from 2.98 ± 1.52 μηιοΙ/1 (time Omin) to 5.98 ± 1.43 μηιοΙ/1 (recovery, tim.e 90min).
Although plasma acetyl-carnitine concentrations were related to tissue metabolism variations, the relationships
of substrate fuel exchange to tissue carnitine metabolism between different parts of the body are still unclear.
sential in lipid catabolism (1). Of the different esters
Glucose, lipids and amino acids are the principal acetyl-carnitine without doubt holds an important
sources of energy during exercise. All metabolic proc- position as a molecule able to subtract acetyl (carni-
esses depend on an intermediate acetyl group, prin- tine as acceptor for acetyl units) from acetyl-coenzyme
cipally bound to coenzyme A to form acetyl-coenzyme A, while maintaining a viable pool of coenzyme A,
A. Many researchers have investigated the regulatory as well as storing "active acetate", readily available
factors influencing one of the substrates (carbohy- for trans-acetylation back to acetyl-coenzyme A
drates, lipids or amino acids) relative to the metabolic (2—4).
et Q fp
Investigation of carnitine and acyl-carnitine metabol-
The carnitine "shuttle" mechanism, by which fatty ism in different types of tissue has produced very
acids are transported across the mitochondria mem- interesting results. Considerable difficulties, however,
brane, can produce acyl-carnitine esters and it is es- are encountered in investigating the role of this sub-
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strate in human tissue and in particular in the whole-
body model, due to the relationships between different
tissues and organs. Numerous scientists have there-
fore studied the variations occurring in different phys-
iological and pathological states (5 — 8).
Other authors (9) and our laboratory (10) have dem-
onstrated variations in plasma free carnitine and ace-
tyl-carnitine during physical exercise. Acetyl storage
and utilization, where appropriate, also seem to be
linked to carnitine. Lennon et al. (9) observed that
carnitine palmitoyl transferase activity varied in mus-
cle tissue during training. These observations seem in
agreement with the hypothesis that carnitine is in-
volved at different levels in various tissue functions.
Plasma esterified and free carnitine concentrations
may change in relation to the different tissue substrate
exchange (energy-transfer), and particularly between
liver and muscle. Lennon & Mance (11) studied inter-
organ cooperativity and carnitine metabolism, partic-
ularly carnitine acetyl- and palmitoyl-transferase ac-
tivity in a variety of tissues of female rats, such as
heart, liver, kidney, different skeletal muscle types and
plasma. They concluded, after determining the effects
of chronic endurance training, that an interorgan shift
in carnitine distribution occurs. These authors pro-
posed that the carnitine status is important in several
human diseases. This type of research indicated that
carnitine (with acetyl-carnitine) metabolism changes
with the physical state of the organism. Physical ex-
ercise can therefore be used experimentally to influ-
ence carnitine metabolism. In fact acetyl-carnitine
plasma concentrations increase in both maximal and
sub-maximal performance (5, 8, 10).
It is known that the liver is a key apical organ in fat
biosynthesis, mobilization and processing, and that
carnitine is an important intermediate in these meta-
bolic processes. Evidence is lacking, however, for
cooperativity between the liver and other tissues (such
as adipose and muscle tissues) with respect to the
utilization of carnitine and the acetyl group. We there-
fore investigated plasma acetyl-carnitine variations in
a pathological state involving altered hepatic function.
We studied the effects of exercise on free carnitine
and acetyl-carnitine plasma concentrations in liver
diseases such as hepatic cirrhosis, in which a varied
acetyl-carnitine metabolism is supposed (12—15), and
during physical exercise, which results in plasma car-
nitine metabolism variations. The chronic persistent
hepatopathic patient, without important handicaps
which impede muscular exercise, and able to sustain
a physical performance at exhaustion, could be a
suitable model. Thus this type of subject could provide
a model for studying carnitine and energy substrate
exchange between liver and other tissues. The litera-
ture contains only limited data on the capacity for
energy fuel substrate exchange during and after mod-
erate physical exercise performance in these subjects
(16). We therefore investigated controls ("normal",
without illness in relation to metabolism) and chronic
persistent hepatitis subjects before, during exercise
and recovery, to verify whether energy requirements
modify free carnitine and acetyl-carnitine plasma con-
centrations, and whether these variations could indi-
cate an interorgan exchange in these two types of
subject.
Materials and Methods
Subjects
Chronic hepatitis patients
Nine male patients with chronic persistent hepatitis, mean age
30 years (range 18—43 years) entered the study. The diagnosis
of chronic persistent hepatitis was confirmed histologically in
each case according to De Groote's classification (17); impair-
ment of liver function was also studied by measuring the in-
creased concentrations of bilirubin (total and conjugated), alan-
ine aminotransferase, aspartate aminotransferase, -glutamyl
transferase (tab. 1).
Control patients
Seven male healthy subjects, mean age 27 years (range 26 — 30
years) were selected as controls. They were recruited among the
laboratory staff, were sedentary, with no regular practice of
sport, and following a well-balanced diet.
Control subjects and chronic persistent hepatitis patients were
voluntary, and informed of the nature and purpose of the study.
Exercise protocols
All subjects were kept on a low carnitine balanced diet (ca. 10
MJ/d = 2400 kcal/d; 60% carbohydrate, 25% fat, 15% protein)
48 h before the test. In the morning, after an overnight fast,
they performed a maximal (to exhaustion) exercise on a cy-
cloergometer (model 300 Quiton Instrument) with 25 Watt
energy load every 2 min. The exercise was continued for 20 min
unless the subject was unable to continue because of symptoms
of fatigue. A week later, under the same conditions, they per-
formed a second submaximal test (50% of their previously
determined maximal oxygen consumption [V02max]) for 60 min.
Collection of blood samples
Blood samples (maximal excercise) were drawn at rest (at
0 min), at exhaustion (at 20 min, end of exercise) and at 30 min
after the end of exercise (at 50 min, recovery). Blood samples
(submaximal exercise) were drawn at rest (at 0 min), at 30 min,
and at 60 min (the end of exercise) and at 30 min post-exercise
(at 90 min, recovery).
Suitable sodium heparinized blood, was centrifuged and plasma
was stored at —20 °C until analysis for free fatty acids, carni-
tine, acetyl-carnitine, lactate, and insulin. For glucagon analysis
2.5 ml of blood were collected in 0.25 ml of aprotinin (Trasy-
lol®)/EDTA solution (500 · 103 KIU/120 g per 1). One millilitre
of blood was immediately deproteinized in 1.0 ml perchloric
acid (1 mol/1) for measurement of the ß-hydroxybutyrate con-
centration.
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Tab. 1. Routine serum chemistries, determined in reference subjects, ranges are
L-aspartate : 2-oxoglutarate aminotransferase, 0 — 45 U/l,
L-alanine : 2-oxoglutarate aminotransferase, 0 — 50 U/l,
γ-glutamyl-peptide : aminoacid γ-glutamyltransferase, 3 — 65 U/l,
orthophosphoric monoester phosphohydrolase, 30 — 115 U/l,
bilirubin (total) 2.0-17 μηιοΙ/1, (direct) 0.0-3.4 μηιοΙ/1.
Data expressed as mean values (± SEM); n, number of subjects
Controls (n = 5)
Hepatopathics (n
Aspartate
amino-
transferase
U/l (*)
22
(2)
= 5) 76
(20)
Alanine
amino-
transferase
U/l (*)
28
(4)
152
(55)
Total
bilirubin
μιηοΐ/ΐ (*)
10.3
(1.1)
17.5
(3.5)
Direct
bilirubin
μηιοΙ/1 (*)
0.54
(0.35)
3.08
(1.0)
γ-Glutamyl-
transferase
U/l (*)
23
(6)
47
(7)
Alkaline
phosphatase
U/l (*)
52
(6)
78
(10)
(*) p < 0.05 control vs hepathopatic subjects; statistical comparisons were made using Student's t-test.
Assay methods
Plasma free fatty acids, -hydroxybutyrate, glucose, lactate
were assayed by conventional enzymatic methods (18 — 20).
Plasma insulin and glucagon concentrations were assayed by
conventional radioimrmmoassay (RIA) with commercial kits
purchased from Sorin Biomedica and BYK, respectively. Serum
bilirubin and enzymes were assayed according to routine lab-
oratory methods and according to the recommendation of
IFCC Expert Panel for Enzymes at 37 °C. Plasma free carnitine
and acetyl-carnitine were analysed by an enzymatic assay as
previously described (21). Plasma sample (1.0 ml) was placed
on a minicolumn (55 χ 15 mm Sephadex-G25), and the column
eluted with assay buffer. Two millilitres of sample (6th and 7th
1.0 ml elution fractions) were collected and divided into two
aliquots (1.0 ml each) for direct free carnitine assay, or lyo-
philized for acetyl-carnitine assay.
and 0.010 ml carnitine acetyl-transferase (80 kU/1, 1 g/1) was
added to start the reaction. It was then possible to measure
fluorimetrically (excitation 337 nm; emission 457 nm) the newly
formed NADH in the solution. Equilibrium was reached after
7 min and the fluorescence intensity variations were referred to
a standard curve (linear throughout 2.5-20.0 μηιοΙ/1). For the
acetyl-carnitine assay, the within-batch imprecision calculated
from duplicate estimation of patient sample, was 11%; the
between-batch imprecision, similarly calculated, was 14%. The
mean concentration in healthy subjects was 2.5 + 0.2 μπιοΐ/ΐ
(mean + SEM, n = 21). The assay has a minimum detection
limit of 1.4 μηιοΐ/l estimated from 3 standard deviations of a
sample without acetyl-carnitine.
The reagents used were of the highest purity commercially
available (analytical grade).
Free carnitine assay
Acetyl-CoA (15 mmol/1) 0.05 ml, 5,5'-dithiobis(2-nitroben-
zoic)acid (10 mmol/1) 0.01 ml, and ethylenedinitrilo tetra-acetic
acid (EDTA, 50 mmol/1) 0.025 ml were added to each eluted
sample (0.900 ml). After 10 min at the constant temperature of
25 °C, carnitine acetyl-transferase (EC 2.3.1.7 - 80 kU/l) (0.010
ml) was added to start the reaction and absorbance was meas-
ured at 412 nm. Reaction equilibrium was reached after 7 min
and the absorbance (after 30 min) was referred to a standard
curve (linear throughout the concentration assayed range
10 — 50 μηιοΙ/1). For the plasma free carnitine assay, the within-
batch imprecision calculated (using replicated analysis) from
duplicate estimation of patient samples, was 4%; the between-
batch imprecision, similarly calculated, was 9%. The mean
concentration in healthy subjects was 33 ± 2 μπιοΐ/l (mean
± SEM, n = 19). The assay has a minimum detection limit of
5 μηιοΙ/1 estimated from 3 standard deviations of a sample
without carnitine.
Acetyl-carnitine assay
Malic acid (100 mmol/1) 0.010 ml, EDTA (25 mmol/1) 0.0125
ml, nicotinamide adenine dinucleotide (NAD, free acid, grade
II, 98%, 5 mmol/1) 0.025 ml, coenzyme A (CoA-SH free acid,
grade I, lyophilisate, 5 mmol/1) 0.005 ml, malate dehydrogenase
(EC 1.1.1.37 from pig heart mitochondrial suspension, 1 g/1,
1.2 kU/1) 0.005 ml, citrate synthase (EC 4.1.3.7 crystallized
1 g/1, 110 kU/1) 0.005 ml, were mixed to form a medium and
0.070 ml of this medium was added directly in a cuvette to
sample (0.500 ml) previously prepared by regeneration of ly-
ophilized powder. Fluorescence intensity was then measured
Stat is t ical ana lys i s
All values are reported as means ± standard deviation (SD)
or standard error of the mean (SEM). Statistical significance
(defined as p < 0.05) of differences between different suitable
groups was assessed by analysis of variance and by t test.
Results
In patients with chronic hepatitis, concentrations of
blood glucose before, during, and after maximal mus-
cular exercise did not differ significantly from those
of normal subjects (tab. 2 and 3), although normal
individuals showed higher concentrations than indi-
viduals with liver disease after maximal exercise.
In controls, concentrations of plasma lactate after
maximal exercise were significantly higher than in the
hepatitis group (fig. 1). After prolonged submaximal
exercise, concentrations of plasma lactate did not
differ significantly between the groups.
Before, during and after maximal exercise, plasma
free fatty acids did not differ between the groups (fig.
2). After submaximal exercise, concentrations in-
creased significantly in both groups (fig. 2), although
plasma free fatty acid concentrations of individuals
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Tab. 2. Concentrations of plasma lactate (mmol/1), free carnitine (μηιοΐ/ΐ), acetyl-carnitine (μηιοΙ/1), free fatty acids (μπιοΐ/ΐ),
glucagon (μ§/1), insulin (mU/1) and blood -hydroxybutyrate (mmol/1), glucose (mmol/1) measured in control subjects
before, during, and after maximal and submaximal muscular exercise. Data expressed as mean value ± SD; n, number
of subjects.
Maximal exercise group
Times (min)
Plasma lactate
Plasma free carnitine
Plasma acetyl-carnitine
Plasma free fatty acids
Plasma glucagon
Plasma insulin
Blood -hydroxybutyrated
Blood glucose
mean
± SD
n
mean
± SD
n
mean
± SD
n
mean
± SD
n
mean
± SD
n
mean
± SD
n
mean
± SD
n
mean
± SD
n
0
1.75
0.36
5
24.00
5.29
5
1.99
1.36
7
321
144
7
_
—
-
_
-
0.07
0.05
7
4.46
0.87
7
20
15.39a
2.02
5
22.60
3.98
5
4.83a
2.60
7
304
137
7
_
—
-
—
-
0.09
0.07
7
5.09
1.18
7
50
7.90a'b
1.26
5
18.20
6.05
5
4.93
3.39
7
365
95
7
—
—
—
—
—
-
0.12
0.07
7
5.49
1.54
7
Submaximal exercise
Times (min)
0
1.75
0.58
5
28.00
4.69
5
1.89
1.70
6
398
138
7
110
53
7
10
4
7
0.06
0.02
7
4.44
0.50
7
30
2.69
1.34
5
25.80
2.64
5
2.92a
2.09
6
304a
109
7
108
69
7
T
2
1
0.07
0.05
7
4.05
0.45
7
group
60
1.45
0.69
5
25.00
5.18
5
2.95
2.22
6
499
143
7
111
69
7
6a
3
7
0.06
0.04
7
3.97
0.50
7
90
1.25
0.62
5
28.00
3.85
5
4.32a-b
2.22
6
614a
288
7
120
78
7
8
4
6
0.18
0.15
7
4.37
0.53
7
a
 p < 0.05 vs basal
b
 p < 0.05 vs time 20 min
c
 p < 0.05 vs time 60 min
d
 p < 0.05 anova test (submaximal exercise test)
with liver disease were slightly, but not significantly,
higher than those in control subjects.
The blood -hydroxybutyrate concentrations, as
shown in figure 3, decreased, but not significantly,
during maximal exercise in hepatitis subjects, whereas
during submaximal exercise the increase was evident
in both groups only during recovery.
Before, during and after maximal and submaximal
exercise, plasma free carnitine did not differ between
the two groups (tab. 2 and 3) and did not vary
significantly within the same group.
Plasma acetyl-carnitine before, during and after max-
imal exercise in hepatitis subjects did not differ, while
in normal subjects it increased (fig. 4). After submax-
imal exercise, acetyl-carnitine increased in both the
chronic hepatitis subjects and the controls.
Plasma insulin concentrations, shown in tables 2 and
3, were significantly different (p = 0.05) between con-
trols and patients, while plasma concentrations were
significantly decreased only for controls; glucagon
concentrations also were higher in patients but not
significantly (tab. 2 and 3).
Discussion
It is generally agreed that plasma free fatty acids are
the primary fuel source for energy metabolism when
glucose is not readily available, as in patients with
diminished hepatic glycogen storage, i. e. in cirrhotic
patients (22). The present data are in accordance with
this view; plasma free fatty acid concentrations were
in patients clearly higher at the end of submaximal
exercise and during recovery (tab. 2 and 3). Moreover,
increasing blood glucose concentrations during max-
imal exercise were observed in controls, but not in
hepatopathic subjects; although this difference was
not statistically significant, it does suggest defective
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Tab. 3. Concentrations of plasma lactate (mmol/1), free carnitine (μηιοΐ/ΐ), acetyl-carnitine (μιηοΙ/1), free fatty acids (μηιοΙ/1),
glucagon (μ§/1), insulin (mU/1), blood -hydroxybutyrate (mmol/1), and blood glucose (mmol/1) measured in patients
before, during, and after maximal and submaximal muscular exercise. Data expressed as mean values + SD; n, number
of subjects.
Maximal exercise group
Times (min)
Plasma lactate
Plasma free carnitine
Plasma acetyl-carnitine
Plasma free fatty acids
Plasma glucagon
Plasma insulin
Blood -hydroxybutyrated
Blood glucose
mean
± SD
n
mean
± SD
n
mean
± SD
n
mean
± SD
n
mean
+ SD
n
mean
±SD
n
mean
± SD
n
mean
± SD
n
0
1.63
0.87
9
21.40
7.47
5
3.26
2.18
9
336
103
9
—
—
-
12
2
4
0.05
0.06
5
4.24
0.72
9
20
8.89a
2.05
9
18.60
5.54
5
4.09
2.23
9
336
86
9
—
—
-
14
7
4
0.02
0.02
5
4.16
0.64
9
50
6.05a-b
2.22
9
26.40
6.05
5
4.30
2.02
9
375
182
9
_
—
-
14
3
4
0.08
0.05
5
4.53
0.88
9
Submaximal exercise group
Times (min)
0
1.56
0.79
9
25.00
7.01
5
2.60
1.30
5
472
133
9
113
32
9
14
9
9
0.08
0.05
7
4.38
0.42
9
30
3.06
1.24
9
25.20
6.79
5
2.79
1.89
5
393
147
9
120
39
9
9
4
9
0.07
0.04
7
3.90
0.53
9
60
1.87
0.77
9
20.00
4.52
5
3.44
1.31
5
699a
295
9
136
37
9
7
3
9
0.14
0.11
7
3.93
0.54
9
90
1.46
0.57
9
27.60
7.14
5
5.98a
1.43
5
698a
181
9
124
33
9
7
4
9
0.26
0.20
7
4.07
0.75
9
a
 p < 0.05 vs basal
b
 p < 0.05 vs time 20 min
d
 p < 0.05 anova test (submaximal exercise test)
liver gluconeogenesis as proposed by Campillo et al.
(6).
Plasma free carnitine concentrations showed no vari-
ations, while it seems confirmed that plasma acetyl-
carnitine was, even if not significantly, elevated in
patients (controls: 1.94 ± 1.53 μιηοΐ/l (η = 13); pa-
tients: 3.02 + 1.94 μιηοΐ/l (η = 14); all values for
times 0 min of maximal and submaximal tests).
Plasma free carnitine concentrations in hepatopathic
patients, studied by other authors, are different and
widely distributed (12 — 15). Some of these results
possibly are in disagreement with our results, because
our patients did not have a severe hepatic dysfunction,
and furthermore because the nutritional status was
different. We measured plasma free carnitine and ace-
tyl-carnitine in patients with chronic hepatitis without
advanced liver disease or malnutrition, and who had
followed a prescribed diet three days before the study.
Discrepancy among different results might also be
due to the use of different analysis methods and to
the different nutritional states of subjects. In fact
spectrophotometric methods were used in some lab-
oratories, and radioenzymatic in others, to determine
free carnitine and acetyl-carnitine plasma concentra-
tions.
A significant increase of plasma free fatty acid con-
centrations at the end of the submaximal exercise and
during the recovery confirmed that the energy supply
consisted of lipids, both in controls and in patients.
Subjects with chronic liver disease undergoing maxi-
mal exercise showed impaired carnitine metabolism;
their plasma acetyl-carnitine concentrations did not
increase with exercise, as in controls (p < 0.05 basal
vs 20 min), probably because of a decreased metab-
olism of carbohydrates in the liver. This also probably
explains why, during maximal exercise, plasma lactate
in patients increased less than in control subjects.
Present observations seem in agreement with DeLissio
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(16) who verified that, during exercise, cirrhotic sub-
jects derived a significantly greater percentage of their
total energy expediture from lipid oxidation and less
from glucose oxidation, compared with the control
subjects. The fact that our results do not agree with
other previous observations (6) could be related to a
different type of patient and a different experimental
protocol. In fact our patients had only very slightly
increased insulin plasma concentrations.
We measured the decreased plasma ß-hydroxybutyr-
ate concentrations in relation to their utilization in
peripheral tissue; lower ß-hydroxybutyrate concentra-
tions during maximal exercise reflect increased oxi-
dation of this ketone body, because it provides a good
substrate for muscle metabolism during exercise, but
it also indicates agreement with the fact that glycolysis
is less active in these patients than in controls.
Our subjects were studied during muscular exercise,
in which plasma free carnitine decreased and plasma
acetyl-carnitine increased as a consequence mainly of
activation of fat oxidation (2, 5, 18). On the other
hand, Lennon et al. (11) demonstrated in rats an
interorgan shift in carnitine distribution in response
to chronic training, suggesting that the majority of
acyl-carnitines formed can be transported, during
muscular exercise, to the liver for glucose or ketone
body formation.
Carlin et al. (5) proposed that the mechanism respon-
sible for the increased plasma acetyl-carnitine in max-
imal muscular exercise could partly be explained by
the different hormonal profiles (6). During submaxi-
mal exercise, our hepatopathic subjects showed no
significant plasma insulin concentration variations,
and the pattern of acetyl-carnitine was the same as in
normal subjects.
Conclusion
The different acetyl-carnitine concentrations during
maximal and submaximal exercise in the two groups
and in the two types of exercise, could be explained
on the basis of the hypothesis that the increase in
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plasma acetyl-carnitine is related to its exchange be-
tween muscle and liver. During both maximal and
submaximal exercise, the patients showed a lower
acetyl-carnitine concentrations variation than con-
trols, who demonstrated a significant increase (0 vs
20 min p < 0.05), possibly due to a higher production.
With submaximal exercise, hormonal control is more
effective, and it is evident that free fatty acids are
utilized by the livers of both controls and patients
(23). These observations seem in agreement with the
hypothesis that acetyl-carnitine is exchanged between
muscle and liver via the blood circulation (24). For a
complete knowledge of this inter-organ cooperation
more investigation is needed, particularly about me-
tabolite turnover, liver blood flow and muscle blood
flow.
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